New combo therapy targets Hard-to-Treat tumors
NCT ID NCT03444714
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This early-stage study tested a new drug called RiMO-301, injected directly into tumors, combined with radiation therapy. It involved 32 adults with advanced cancers that could not be cured by standard treatments. The main goal was to find the safest dose and see if the combination could shrink tumors or ease symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.